Maintenance with single agent bevacizumab fails to improve disease-control in metastatic colorectal cancer

摘要

The availability of biologicals,such as anti-EFGR and anti-VEGF antibodies in combination with chemotherapy(ChT),has improved prognosis of metastatic colorectal cancer(mCRC).However,the administration of drug combinations for a prolonged time implies an increased rate of toxicities,which is why some strategies to de-escalate treatment intensity have been studied.